Otto Cheung

Otto is an Approach-specific Scientist of ORI Capital. Otto’s primary responsibilities include conducting science and technology due diligence as well as certain post investment portfolio activities. Prior to joining ORI Capital, Otto worked as a Business Analyst in the healthcare strategy consulting team of Deloitte Consulting. During his academic career, Otto's major research focuses were cancer epigenetics and cancer immunology. Otto received a BSc in Life Science and a PhD from the Chinese University of Hong Kong.